Stegent Equity Advisors
ABBV icon

Stegent Equity Advisors’s AbbVie ABBV Stock Holding History

Stegent Equity Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-6,868
Closed -$1.73M – 94
2026
Q2 		$1.73M Sell
6,868
-882
-11% -$190K 1.24% 30
2026
Q1 		$1.69M Sell
7,750
-3,179
-29% -$705K 1.44% 23
2025
Q4 		$2.5M Buy
10,929
+7,400
+210% +$1.69M 1.95% 11
2025
Q3 		$817K Sell
3,529
-4,471
-56% -$910K 0.67% 47
2025
Q2 		$1.48M Buy
8,000
+3,538
+79% +$658K 1.31% 26
2025
Q1 		$935K Buy
+4,462
New +$867K 0.95% 33
2024
Q3 		– Sell
-1,917
Closed -$329K – 89
2024
Q2 		$329K Sell
1,917
-3,659
-66% -$606K 0.34% 57
2024
Q1 		$1.02M Buy
5,576
+3,977
+249% +$685K 1.03% 37
2023
Q4 		$248K Buy
+1,599
New +$233K 0.29% 59

Other funds holding ABBV

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Stegent Equity Advisors's ABBV Position: Q3 2026 in Review

Stegent Equity Advisors sold out of AbbVie (ABBV) in Q3 2026, closing a stake of 6,868 shares — an estimated $1.73M sold.

Stegent Equity Advisors first reported a position in ABBV in Q4 2023 and held it in 9 quarters. The position peaked at $2.5M in Q4 2025. 3,526 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Stegent Equity Advisors reported no remaining AbbVie position as of Q3 2026 after selling out during the quarter.
  • Stegent Equity Advisors sold 6,868 AbbVie shares in Q3 2026, an estimated $1.73M.
  • Stegent Equity Advisors first reported a position in AbbVie in Q4 2023 and held it in 9 quarters.
  • Stegent Equity Advisors's AbbVie position peaked at $2.5M in Q4 2025.
  • 3,526 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Stegent Equity Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.